Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity

BACKGROUND: Delayed-release dimethyl fumarate (DMF) demonstrates sustained efficacy and safety for relapsing forms of MS. Absolute lymphocyte count (ALC) is reduced initially, then stabilizes on treatment. OBJECTIVE: PROCLAIM, a 96-week, prospective, open-label, phase 3b study, assessed lymphocyte s...

Descripción completa

Detalles Bibliográficos
Autores principales: Longbrake, Erin E, Mao-Draayer, Yang, Cascione, Mark, Zielinski, Tomasz, Bame, Eris, Brassat, David, Chen, Chongshu, Kapadia, Shivani, Mendoza, Jason P, Miller, Catherine, Parks, Becky, Xing, Diana, Robertson, Derrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023410/
https://www.ncbi.nlm.nih.gov/pubmed/32716690
http://dx.doi.org/10.1177/1352458520937282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023410/
https://www.ncbi.nlm.nih.gov/pubmed/32716690
http://dx.doi.org/10.1177/1352458520937282

Ejemplares similares